Skip to main content

Advertisement

Table 1 Immune checkpoint inhibitors approved by the Food and Drug Administration in USA

From: Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports

  Ipilimumab CTLA-4 Nivolumab PD-1 Pembrolizumab PD-1 Atezolizumab PD-L1 Avelumab PD-L1 Durvalumab PD-L1
Malignancy
 Melanoma √*(3/2011) √*(12/2014) √*(9/2014)    
 Non-small cell lung cancer   √ (3/2015) √ (10/2015) √ (10/2016)   
 Renal cell carcinoma   √ (11/2015)     
 Hepatocellular carcinoma   √ (9/2017)     
 Classical Hodgkin’ s lymphoma   √ (5/2016) √ (3/2017)    
 Head & neck squamous cell carcinoma4   √ (11/2017) √ (8/2016)    
 Urothelial Carcinoma   √ (2/2017) √ (5/2017) √*(5/2016) √ (5/2017) √*(5/2017)
 Colorectal cancer with high msi/mrd   √ (8/2017)     
 Gastric cancer    √ (9/2017)    
 Solid tumor with high msi/mrd    √ (7/2017)    
 Merkel-cell carcinoma      √* (3/2017)  
 Bladder Cancer     √ (04/2017)   
  1. *First indication approval date by FDA